16 September 2024

Dear Healthcare Professional,

Versacloz (clozapine) 50 mg/mL oral suspension syringe change

Douglas Pharmaceuticals Ltd would like to notify you of a change to the 'look' of the Versacloz syringes.

- We have had to switch providers of the syringes contained within the Versacloz box and will be moving from one syringe/adaptor supplier (Baxter) to another (HDB).
- The syringes and adaptors look slightly different, but the markings are the same. (refer to the photos below)
- There are no safety concerns with these changes.

Current Syringes and PIBA (Baxter)	Proposed New Syringes and PIBA (HDB)
	

Please ensure that all your relevant staff are made aware of the contents of this letter and that the information is communicated to your patients.

Reporting adverse events

Reporting suspected adverse reactions has an important role in monitoring the benefit/risk balance of medicines. please report any suspected adverse events via email to Douglas Pharmaceuticals Ltd at drugsafety@douglas.co.nz.

Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) at https://pophealth.my.site.com/carmreportnz/s/. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset and treatment dates.

The Data Sheet for Versacloz Suspension is available at: https://medsafe.govt.nz/profs/Datasheet/v/Versaclozsusp.pdf.

If you have any question related to this product, please phone 0800 368 452, or +64 9 835 0660 or alternatively contact us via our website at www.douglas.co.nz (Contact us)

Kind regards,

Regulatory & Clinical Affairs Strategic Business Partner

+64 9 835 0660

Douglas Pharmaceuticals Ltd
Central Park Drive, Lincoln
PO Box 45 027, Auckland 0651

www.douglas.co.nz